Alpha 2.0
Login Register
» Authors » Matthias Zaiss

Matthias Zaiss

Explore the profile of Matthias Zaiss including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 179
Followers 0
Related Specialties
Oncology
Hematology
General Medicine
Top 10 Co-Authors
Norbert Marschner
Diana Luftner
Thomas Decker
Volkmar Muller
Nadia Harbeck
Thomas Wolff
Karin Potthoff
Marcus Schmidt
Anja Welt
Andreas Schneeweiss
Published In
Oncol Res Treat
Eur J Haematol
Geburtshilfe Frauenheilkd
Breast Care (Basel)
Exp Hematol
Affiliations
Soon will be listed here.
Recent Articles
1.
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry
Thill M, Zahn M, Welt A, Nusch A, Zaiss M, Engelken K, et al.
Int J Cancer . 2024 Dec; 156(9):1770-1782. PMID: 39707595
Cyclin-dependent kinase 4/6 inhibitors (CDKIs) in combination with endocrine therapy (ET) are the standard-of-care in the first-line treatment of HR-positive, HER2-negative metastatic breast cancer. In the absence of direct head-to-head...
2.
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial
Welslau M, Potthoff K, Zaiss M, Muller L, Brucker C, Salat C, et al.
Oncol Res Treat . 2024 Nov; 48(1-2):14-25. PMID: 39551040
Introduction: The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L...
3.
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study
Schwaner I, Kuhn T, Losem C, Wolff T, Otremba B, Zaiss M, et al.
Ann Hematol . 2024 Feb; 103(6):2013-2020. PMID: 38421404
Venetoclax is active in both frontline and relapsed/refractory settings for the treatment of chronic lymphocytic leukemia (CLL). Although the prevalence and severity of tumor lysis syndrome (TLS) are well characterized...
4.
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study
Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D, Distelrath A, et al.
Breast Care (Basel) . 2024 Feb; 19(1):1-9. PMID: 38384488
Introduction: Prognosis of patients diagnosed with HER2+ early breast cancer (eBC) has substantially improved, but distant recurrences impacting quality of life and survival still occur. One treatment option for extended...
5.
Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or...
Decker T, Zaiss M, Klein D, Hahn A, Hagen V, La Rosee P, et al.
Breast Care (Basel) . 2024 Feb; 19(1):49-61. PMID: 38384487
Background: We investigated the efficacy and health-related quality of life (HRQoL) in patients receiving either ribociclib plus endocrine therapy (ET) or chemotherapy with/without bevacizumab as first-line treatment of metastatic hormone...
6.
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
Martens U, Schroder J, Bengsch F, Sellmann L, Busies S, Frank-Gleich S, et al.
BMC Cancer . 2023 Jun; 23(1):543. PMID: 37312086
Background: Precision oncology, defined as treatment of patients with targeted therapies matched to specific molecular alterations, has entered routine clinical practice. Particularly in patients with advanced cancer or hematologic malignancies,...
7.
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic...
Degenhardt T, Fasching P, Luftner D, Muller V, Thomssen C, Schem C, et al.
Trials . 2023 May; 24(1):338. PMID: 37198674
Background: Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2...
8.
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
Thill M, Wimberger P, Grafe A, Klare P, Luedtke-Heckenkamp K, Reichert D, et al.
Breast Cancer Res Treat . 2022 Sep; 196(2):311-321. PMID: 36094611
Purpose: NIS HELENA documented outcomes in clinical routine practice of first-line therapy with P plus T and docetaxel (D) of patients with advanced HER2-positive BC and prior (neo)adjuvant T. Methods:...
9.
Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO
Zaiss M, Uhlig J, Zahn M, Decker T, Lehmann H, Harde J, et al.
Oncol Res Treat . 2021 Sep; 44(11):613-621. PMID: 34496363
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect persisting after completion of neurotoxic chemotherapies. This observational study was designed to evaluate the effectiveness of the dietary supplement OnLife®...
10.
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, et al.
JAMA Oncol . 2019 Aug; 5(11):1556-1564. PMID: 31465093
Importance: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which...